Phio Pharmaceuticals Corp (PHIO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $9.21M
Last updated: Nov 17, 2026 at 11:00 AM ET
Phio Pharmaceuticals Corp (PHIO) Financials: Revenue, Profit and Cash Flow
Phio Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$8.70M, operating cash flow was -$7.98M and free cash flow was -$7.99M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$4.14M.
Revenue and Margins
The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $9.22M.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0 | N/A | N/A | N/A | N/A |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $6.00K | N/A | 100.0% | -180400.0% | -180433.3% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2019 | $21.00K | -84.8% | 100.0% | -42795.2% | -42419.0% |
| Dec 2018 | $138.00K | +820.0% | 100.0% | -5336.2% | -5333.3% |
| Dec 2017 | $15.00K | -21.1% | 100.0% | -93746.7% | -83013.3% |
| Dec 2016 | $19.00K | N/A | 100.0% | -47447.4% | -47336.8% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $6.00K | $0 | $0 | $0 | $21.00K | $138.00K | $15.00K | $19.00K |
| Gross profit | $0 | $0 | $6.00K | $0 | $0 | $0 | $21.00K | $138.00K | $15.00K | $19.00K |
| Research and development | $4.62M | $3.64M | $6.33M | $7.01M | $8.89M | $3.72M | $4.30M | $4.33M | $10.07M | $5.42M |
| Operating income | -$9.22M | -$7.39M | -$10.82M | -$11.46M | -$13.51M | -$8.79M | -$8.99M | -$7.36M | -$14.06M | -$9.02M |
| Net income | -$8.70M | -$7.15M | -$10.83M | -$11.48M | -$13.29M | -$8.79M | -$8.91M | -$7.36M | -$12.45M | -$8.99M |
| EBITDA | -$9.21M | -$7.35M | -$10.64M | -$11.29M | -$13.10M | -$8.72M | -$8.84M | -$7.28M | -$14.00M | -$8.96M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $70.00K | $0 | $0 | $0 | $6.00K | $0 |
| Gross profit | $0 | $0 | -$1.00K | $0 | $0 | $0 | $35.00K | $0 | $0 | $0 | $6.00K | $0 |
| Operating income | -$4.27M | -$4.17M | -$2.53M | -$2.50M | -$2.31M | -$1.87M | -$1.67M | -$1.59M | -$1.91M | -$2.21M | -$1.90M | -$2.78M |
| Net income | -$4.14M | -$4.00M | -$2.37M | -$2.39M | -$2.17M | -$1.77M | -$1.63M | -$1.52M | -$1.85M | -$2.15M | -$1.90M | -$2.78M |
Balance Sheet
As of Dec 2025, cash and equivalents of $21.03M were 97.9% of total assets of $21.49M, against total liabilities of $1.34M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $21.49M | $5.74M | $9.36M | $12.81M | $25.17M | $15.74M | $8.04M | $15.32M | $4.10M | $13.40M |
| Current assets | $21.48M | $5.74M | $9.32M | $12.45M | $24.73M | $15.16M | $7.30M | $15.15M | $3.83M | $13.11M |
| Cash and equivalents | $21.03M | $5.38M | $8.49M | $11.78M | $24.06M | $14.24M | $6.93M | $14.88M | $3.58M | $12.91M |
| Total liabilities | $1.34M | $1.01M | $1.63M | $1.97M | $3.24M | $2.72M | $2.29M | $1.74M | $2.27M | $2.54M |
| Short-term debt | N/A | N/A | $35.00K | $135.00K | $125.00K | $116.00K | $107.00K | N/A | N/A | N/A |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | $231.00K | $0 | N/A | N/A | N/A |
| Shareholder equity | $20.15M | $4.72M | $7.73M | $10.84M | $21.93M | $13.02M | $5.75M | $13.58M | $1.83M | $10.86M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $14.31M | $17.41M | $21.49M | $11.51M | $11.30M | $13.44M | $5.74M | $5.87M | $5.30M | $6.85M | $9.36M | $9.54M |
| Total liabilities | $1.71M | $950.00K | $1.34M | $1.67M | $1.21M | $1.27M | $1.01M | $919.00K | $1.52M | $1.25M | $1.63M | $2.33M |
| Cash and equivalents | $13.00M | $17.03M | $21.03M | $10.71M | $10.78M | $13.28M | $5.38M | $5.39M | $4.70M | $6.47M | $8.49M | $8.41M |
| Shareholder equity | $12.60M | $16.46M | $20.15M | $9.84M | $10.10M | $12.17M | $4.72M | $4.95M | $3.77M | $5.60M | $7.73M | $7.21M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.98M | -$7.11M | -$10.75M | -$12.13M | -$11.86M | -$8.80M | -$8.64M | -$7.52M | -$9.51M | -$7.76M |
| Capital expenditures | $12.00K | $1.00K | $5.00K | $121.00K | $51.00K | $19.00K | $72.00K | $5.00K | $203.00K | $4.00K |
| Free cash flow | -$7.99M | -$7.11M | -$10.75M | -$12.25M | -$11.91M | -$8.82M | -$8.72M | -$7.53M | -$9.72M | -$7.76M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | $4.09M | $1.00K | N/A | N/A | N/A |
| Investing cash flow | -$12.00K | $8.00K | -$5.00K | -$121.00K | -$51.00K | -$19.00K | -$72.00K | -$5.00K | -$103.00K | $5.35M |
| Financing cash flow | $23.64M | $4.00M | $7.41M | -$26.00K | $21.72M | $16.13M | $772.00K | $18.82M | $292.00K | $10.20M |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$4.04M | -$4.00M | -$2.08M | -$2.08M | -$2.54M | -$1.27M | -$1.37M | -$1.95M | -$1.78M | -$2.01M | -$2.37M | -$2.90M |
| Capital expenditures | N/A | $0 | $0 | $7.00K | $3.00K | $2.00K | $1.00K | $0 | $0 | $0 | $0 | $0 |
| Free cash flow | N/A | -$4.00M | -$2.08M | -$2.09M | -$2.54M | -$1.28M | -$1.37M | -$1.95M | -$1.78M | -$2.01M | -$2.37M | -$2.90M |
Frequently Asked Questions About PHIO
What is Phio Pharmaceuticals' annual revenue?
Phio Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.
Is Phio Pharmaceuticals profitable?
No. Phio Pharmaceuticals reported net income of -$8.70M for the fiscal year ended Dec 31, 2025.
How much free cash flow does PHIO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$7.98M minus capital expenditures of $12.00K produced free cash flow of -$7.99M.
How much debt does Phio Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $21.03M.
PHIO pages: Overview, Earnings, Forecast, Financials, Competitors